Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2007 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00052936
First received: January 24, 2003
Last updated: March 11, 2010
Last verified: June 2007
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating aggressive non-Hodgkin's lymphoma.

PURPOSE: This randomized phase III trial is studying how well giving cyclophosphamide, doxorubicin, vincristine, and prednisone together with or without rituximab works in treating older patients who have aggressive non-Hodgkin's lymphoma. (This trial is no longer randomized as of 6/2005).


Condition Intervention Phase
Lymphoma
Biological: filgrastim
Biological: rituximab
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Time to treatment failure at 3 years within the study and then periodically after study completion [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Complete response rate at 3 years within the study and then periodically after study completion [ Designated as safety issue: No ]
  • Progression rate [ Designated as safety issue: No ]
  • Survival [ Designated as safety issue: No ]
  • Tumor control [ Designated as safety issue: No ]
  • Disease-free survival [ Designated as safety issue: No ]

Estimated Enrollment: 1580
Study Start Date: January 2001
Detailed Description:

OBJECTIVES:

Primary

  • Compare the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with vs without rituximab in elderly patients with aggressive non-Hodgkin's lymphoma.
  • Compare the efficacy of 6 vs 8 courses of CHOP chemotherapy in patients treated with these regimens.
  • Compare the rate of complete remission, rate of primary progression, tumor control, disease-free survival, overall survival, and relapse after radiotherapy in patients treated with these regimens.
  • Compare the safety and side effects of these regimens in these patients.

Secondary

  • Compare short-term and long-term side effects of these regimens in these patients.
  • Compare quality of life of patients treated with these regimens.
  • Compare the cost of these regimens in these patients.
  • Determine relapse in patients treated with these regimens who received involved-field radiotherapy.

OUTLINE: This is a randomized (randomized part of study completed as of 6/2005), open-label, multicenter study. Patients are stratified according to participating center, value for serum lactic dehydrogenase (no greater than upper limit of normal [ULN] vs greater than ULN), bulky disease present (no vs yes), stage (I or II vs III or IV), general ECOG status of patient (0 or 1 vs 2), and age (61 to 70 vs 71-80). Patients are randomized to 1 of 4 treatment arms. Patients with CD20-negative lymphoma are randomized to arms I or II only.

  • Prephase treatment:Patients receive vincristine IV on day -6 and prednisone on day -6 to day 0 before initiating CHOP chemotherapy.
  • Arm I (closed to accrual as of 7/25/2005): Patients receive standard CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 6-12 of each CHOP course. Treatment repeats every 2 weeks for 6 courses.
  • Arm II (closed to accrual as of 7/25/2005): Patients receive standard CHOP chemotherapy and G-CSF as in arm I for a total of 8 courses.
  • Arm III: Patients receive standard CHOP chemotherapy and G-CSF as in arm I. Patients also receive rituximab IV before CHOP every 2 weeks for a total of 8 courses.
  • Arm IV (closed to accrual as of 7/25/2005): Patients receive standard CHOP chemotherapy and G-CSF as in arm II. Patients also receive rituximab IV before CHOP every 2 weeks for a total of 8 courses.

In all arms, treatment continues in the absence of disease progression or unacceptable toxicity.

Beginning 3-6 weeks after completion of the last chemotherapy course, after complete recovery of bone marrow, and after complete remision of mucositis, patients with sites of initial bulky disease or extranodal involvement undergo radiotherapy 5 times a week for 4 weeks.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 1580 patients will be accrued for this study within 5 years.

  Eligibility

Ages Eligible for Study:   61 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement)
  • CD20^+ B-cell lymphoma or CD20^- B-cell and T-cell lymphoma allowed
  • B-cell NHL including the following:

    • Stage III follicular lymphoma
    • Stage III follicular lymphoma and diffuse B-cell lymphoma
    • Lymphoblastic precursor B-cell lymphoma
    • Diffuse large cell B-cell lymphoma

      • Centroblastic
      • Immunoblastic
      • Plasmablastic
      • Anaplastic large cell
      • T-cell-rich B-cell lymphoma
      • Primary effusion lymphoma
      • Intravasal B-cell lymphoma
      • Primary mediastinal B-cell lymphoma
    • Mantle zone lymphoma, blastoid
    • Burkitt's lymphoma
    • Burkitt-like lymphoma
    • Aggressive marginal zone lymphoma (monocytoid)
  • T-cell NHL including the following:

    • Lymphoblastic precursor T-cell lymphoma
    • Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS)

      • Lennert's lymphoma
      • T-zone lymphoma
    • T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type
    • Anaplastic large cell lymphoma

      • ALK^+
      • ALK^-
    • Extranodal NK/T-cell lymphoma, nasal type
    • Intestinal T/NK-cell lymphoma (with or without enteropathy)

      • Hepatosplenic gamma-delta lymphoma
      • Subcutaneous panniculitis-like PTCL
      • Aggressive T/NK PTCL
    • Anaplastic large-cell NHL, NOS
  • Bone marrow involvement no more than 25%
  • No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract

PATIENT CHARACTERISTICS:

Age

  • 61 to 80

Performance status

  • ECOG 0-2 OR
  • Karnofsky 60-100%

Life expectancy

  • Not specified

Hematopoietic

  • WBC at least 2,500/mm^3
  • Platelet count at least 100,000/mm^3

Hepatic

  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • No active hepatitis infection

Renal

  • Creatinine no greater than 2 times ULN

Cardiovascular

  • No Canadian Cardiovascular Society class III or IV angina pectoris
  • No New York Heart Association class III or IV cardiac failure
  • Ejection fraction at least 50%
  • Fractional shortenings at least 25% by echocardiography or nuclear medicine examination

Pulmonary

  • FEV1 at least 50%
  • Diffusion capacity at least 50%

Other

  • No uncontrolled diabetes mellitus
  • No known hypersensitivity to any study medications
  • No other concurrent malignancy
  • HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • No prior chemotherapy

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radiotherapy

Surgery

  • Not specified

Other

  • Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study)
  • No other concurrent lymphoma therapy
  • No concurrent participation in another treatment study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00052936

  Hide Study Locations
Locations
Germany
Haematologisch Onkologische Praxis
Aachen, Germany, 52070
Klinikum St. Marien
Amberg, Germany, D-92224
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie
Ansbach, Germany, 91522
Specialist Practice for Oncology
Aschaffenburg, Germany, 63739
II. Medizinische Klinik
Aschaffenburg, Germany, 63739
Haematologische Praxis
Augsburg, Germany, 86150
Klinikum Augsburg
Augsburg, Germany, D-86156
Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg
Augsburg, Germany, 86150
Kreiskrankenhaus Aurich
Aurich, Germany, D-26603
Regional Hospital Am Plattenwald
Bad Friedrichshall, Germany, 74172
Regional Hospital Bad Hersfeld
Bad Hersfeld, Germany, 36251
Humaine - Clinic
Bad Saarow, Germany, 15523
Krankenhaus Hohe Warte Mediziniche Klinik
Bayreuth, Germany, D-95445
Robert Roessle Comprehensive Cancer Center - Charite Campus Buch
Berlin, Germany, 13125
Haematologisch-Onkologische Schwerpunktpraxis
Berlin, Germany, 13357
Hospital Complex Bernburg
Bernburg, Germany, 06406
Krankenhaus Bietigheim
Bietigheim, Germany, D-74321
Saint Agnes Hospital
Bocholt, Germany, 46397
Knappschaft Krankenhaus
Bochum, Germany, D-44892
Saint Josef Hospital
Bochum, Germany, 44791
Medizinische Poliklinik
Bonn, Germany, D-53111
Rheinische Friedrich-Wilhelms-Universitat
Bonn, Germany, D-53113
DIAKO Ev. Diakonie Krankenhaus gGmbH
Bremen, Germany, 28239
Medizinische Klinik Am Lukas - Krankenhaus
Bunde, Germany, D-32257
General Hospital
Celle, Germany, 29223
Hospital Kuchwald Chemnitz
Chemnitz, Germany, 09113
Medizinische Universitaetsklinik I at the University of Cologne
Cologne, Germany, D-50924
Praxis Fuer Haematologie Internistische Onkologie
Cologne, Germany, D-50677
Cologne-Kalk, Germany, D-51105
Lung Clinic Cologne-Merheim
Cologne-Merheim, Germany, D-51109
Carl - Thiem - Klinkum Cottbus
Cottbus, Germany, 03048
Klinikum Darmstadt
Darmstadt, Germany, D-64283
Saint Johannes Hospital Dortmund
Dortmund, Germany, 44137
Universitatsklinikum Carl Gustav Carus
Dresden, Germany, D-01307
St. Johannes Hospital - Medical Klinik II
Duisburg, Germany, 47166
Franz Hospital Dulmen
Dulmen, Germany, 48249
Florence-Nightingale-Krankenhause, Deaconess Kaiserswerth
Dusseldorf, Germany, 40489
Hans - Susemihl - Krankenhaus
Emden, Germany, 26721
Klinikum Erfurt
Erfurt, Germany, D-99089
St. Antonius Hospital
Eschweiler, Germany, 52249
Universitaetsklinikum Essen
Essen, Germany, 45147
Evangelisches Krankenhaus Essen Werden
Essen-Werden, Germany, 45239
Krankenhaus Nordwest
Frankfurt, Germany, D-60488
Klinikum Frankfurt (Oder) GmbH
Frankfurt/Oder, Germany, D-15236
Evang. Deaconess Hospital Freiburg
Freiburg, Germany, 79110
Municipal Hospital Complex
Fulda, Germany, D-36043
Robert - Koch Hospital
Gehrden, Germany, 30989
Centre for Internal Medicine Gieben
Gieben, Germany, 35392
Universitaetsklinikum Goettingen
Goettingen, Germany, 37075
Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet
Greifswald, Germany, 17489
Staedtisches Klinikum Guetersloh
Gutersloh, Germany, 33332
St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH
Hagen, Germany, 58095
Allgemeines Krankenhaus Hagen
Hagen, Germany, 58095
Universitaetsklinikum Halle
Halle, Germany, D-06120
Krankenhaus Martha-Maria Halle-Doelau gGmbH
Halle, Germany, 06120
Krankenhaus St. Elisabeth und St. Barbara
Halle/Saale, Germany, 06110
Haematologisch-Onkologische Praxis Altona
Hamburg, Germany, D-22767
Asklepios Klinik Nord Heidberg
Hamburg, Germany, 22413
Hamburg, Germany, 20095
University Medical Center Hamburg - Eppendorf
Hamburg, Germany, 20251
Allgemeines Krankenhaus Altona
Hamburg, Germany, 22763
Evangelische Krankenhaus Hamm
Hamm, Germany, 59063
Henriettenstiftung Krankenhaus
Hannover, Germany, 30559
Medizinische Hochschule Hannover
Hannover, Germany, D-30625
Krankenhaus Siloah - Medizinische Klinik II
Hannover, Germany, D-30449
Hannover, Germany, 30159
Oncology Specialists Clinic
Harrislee, Germany, D-24955
Medizinische Universitaetsklinik und Poliklinik
Heidelberg, Germany, D-69115
Thoraxklinik Heidelberg
Heidelberg, Germany, 69126
Regional Hospital Heidenheim
Heidenheim, Germany, 89522
Klinikum Herford
Herford, Germany, D-32049
Marienhospital at Ruhr University Bochum
Herne, Germany, D-44625
Privatklinik Dr. R. Schindlbeck GmbH & Co. KG
Herrsching, Germany, D-82211
Onkologische Schwerpunktpraxis
Hildesheim, Germany, D-31134
Evang. Hospital
Holzminden, Germany, 37603
Medical University Hospital Homburg
Homburg, Germany, D-66421
Hospital Complex Hoyerswerda
Hoyerswerda, Germany, 02977
Klinikum der Friedrich-Schiller Universitaet Jena
Jena, Germany, D-07747
Gemeinschaftspraxis Innere Medizin
Jena, Germany, D-07743
Municipal Hospital Complex of the University
Kaiserslautern, Germany, D-67655
Staedtisches Klinikum Karlsruhe gGmbH
Karlsruhe, Germany, 76133
Red Cross Hospital Kassel
Kassel, Germany, 34121
Staedtisches Krankenhaus Kiel
Kiel, Germany, 23116
Stiftungsklinikum Mittelrhein - Gesundheitszentrum Evangelisches Stift Sankt Martin Koblenz gGmbH
Koblenz, Germany, 56068
Praxis fuer Haematologie und Onkologie
Koblenz, Germany, D-56068
Leonardis Clinic
Kornwestheim, Germany, D-70806
Klinikum Krefeld GmbH
Krefeld, Germany, D-47805
Frankenwald Klinik
Kronach, Germany, 96317
Caritas - Krakenhaus Lebach
Lebach, Germany, 66822
Leipzig, Germany, D-04103
University Leipzig Clinic of Internal Medicine
Leipzig, Germany, 04103
Klinikum "St. Georg" Leipzig
Leipzig, Germany, 04129
Klinikum Lippe - Lemgo
Lemgo, Germany, D-32657
St. Vincenz Hospital Limburg
Limburg, Germany, 65549
St. Bonifatius Hospital Lingen
Lingen, Germany, 49808
Dreifaltigkeits Hospital
Lippstadt, Germany, 59555
Klinikum Ludwigsburg
Ludwigsburg, Germany, D-71640
Municipal Complex of Ludwigshafen
Ludwigshafen, Germany, D-67063
St. Marien Hospital Ludwighafen
Ludwigshafen, Germany, 67067
Universitaetsklinikum Schleswig-Holstein - Campus Luebeck
Luebeck, Germany, D-23538
Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg
Magdeburg, Germany, 39120
Staedtisches Klinikum Magdeburg - Altstadt
Magdeburg, Germany, 39104
Johannes Gutenberg University
Mainz, Germany, 55131
III Medizinische Klinik Mannheim
Mannheim, Germany, D-68305
Marburg, Germany, D-35037
Universitaetsklinikum Giessen und Marburg GmbH - Marburg
Marburg, Germany, D-35043
Regional Hospital Mayen
Mayen, Germany, 56727
Klinikum Minden
Minden, Germany, D-32423
Minden, Germany, D-32427
Ev. Hospital Bethesda
Monchengladbach, Germany, 41061
Hospital Maria-Hilf II
Monchengladbach, Germany, 41063
Monchenglasbach/Rheydt, Germany, D-41239
Evangelisches Krankenhaus - Mulheim
Mulheim/Ruhr, Germany, 45466
St. Marien Hospital - Muelheim an der Ruhr
Mulheim/Ruhr, Germany, 45468
Kreiskrankenhaus Muenchberg
Munchberg, Germany, 95213
Klinikum der Universitaet Muenchen - Grosshadern Campus
Munich, Germany, D-81377
Munich Oncologic Practice at Elisenhof
Munich, Germany, D-80335
Krankenhaus Muenchen Schwabing
Munich, Germany, D-80804
Klinikum der Universitaet Muenchen - Innenstadt Campus
Munich, Germany, D-80336
Municipal Hospital Munich
Munich, Germany, D-81737
Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster
Munster, Germany, D-48129
Regional Hospital Neumarkt
Neumarkt, Germany, 92318
Staedtisches Klinikum Neunkirchen gGmbH
Neunkirchen, Germany, 66538
Lukaskrankenhaus Neuss
Neus, Germany, D-41464
Klinikum Nuernberg - Klinikum Nord
Nuremberg, Germany, D-90340
Klinikum Offenburg
Offenburg, Germany, D-77654
Ev. Hospital Oldenburg
Oldenburg, Germany, 26122
Klinikum Oldenburg
Oldenburg, Germany, D-26133
Hematologische Praxis
Oldenburg, Germany, 26121
Paracelsus - Klinik Osnabrueck
Osnabrueck, Germany, D-49076
Municipal Hospital Complex
Pforzheim, Germany, D-75175
Klinikum Ernst Von Bergmann
Potsdam, Germany, D-14467
Kreiskrankenhaus Radebeul
Radebeul, Germany, D-01445
Krankenhaus St. Elisabeth - Ravensburg
Ravensburg, Germany, 88212
Hematologische Onkologische Praxis
Regensburg, Germany, 93047
Klinikum der Universitaet Regensburg
Regensburg, Germany, 93042
Krankenhaus Barmherzige Brueder Regensburg
Regensburg, Germany, D-93049
Jakobi Krankenhaus
Rheine, Germany, 48431
Klinik und Poliklinik fuer Strahlentherapie - Universitaetsklinikum Rostock
Rostock, Germany, 18059
Rostock, Germany, D-18257
Klinik und Poliklinik fuer Innere Medizin - Universitaet Rostock
Rostock, Germany, 18057
Caritasklinik St. Theresia
Saarbrucken, Germany, 66113
Schwerpunktpraxis fuer Haematologie und Onkologie
Saarbruecken, Germany, D-66113
St. Elizabeth-Klinik Saarlouis
Saarlouis, Germany, 66713
Martin - Luther Hospital
Schleswig, Germany, D-24837
Deaconess Hospital
Schwabisch Hall, Germany, 74523
Leopoldina - Krankenhaus
Schweinfurt, Germany, D-97422
Evang. Jung-Stilling Hospital
Siegen, Germany, 57074
St. Lukas - Clinic Solingen
Solingen, Germany, 42697
Hospital Bad Cannstatt
Stuttgart, Germany, 70374
Klinikum Stuttgart - Buergerhospital
Stuttgart, Germany, 70191
Diakonie Klinikum Stuttgart
Stuttgart, Germany, 70176
Klinik fuer Onkologie - Katharinenhospital Stuttgart
Stuttgart, Germany, 70174
Robert-Bosch-Krankenhaus
Stuttgart, Germany, 70376
St. Elisabeth Hospital Thuine
Thuine, Germany, 49832
Regional Hospital Traunstein
Traunstein, Germany, 83278
Krankenanstalt Mutterhaus der Borromaerinnen
Trier, Germany, D-54290
Krankenhaus Barmherzigen Brueder
Trier, Germany, D-54292
Trier, Germany, D-54290
Hospital Tutzing
Tutzing, Germany, 82327
Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm
Ulm, Germany, 89081
Ev. Hospital Unna
Unna, Germany, 59403
St. Marienhospital - Vechta
Vechta, Germany, 49377
Municipal Hospital Complex
Villingen-Schwenningen, Germany, D-78045
Regional Hospital Waldbrol
Waldbrol, Germany, 51545
Hospital Wetzler
Wetzlar, Germany, 35578
Dr. Horst-Schmidt-Kliniken
Wiesbaden, Germany, 65199
Deutsche Klinik fuer Diagnostik
Wiesbaden, Germany, 65191
Ev. Hospital Witten-Herdecke
Witten, Germany, 58455
Kliniken St. Antonius
Wuppertal, Germany, 42283
University Wurzburg
Wurzburg, Germany, 97070
Municipal Hospital Complex Zwickau
Zwickau, Germany, D-08060
Switzerland
UniversitaetsSpital Zuerich
Zurich, Switzerland, 8091
City Hospital Triemli
Zurich, Switzerland, 8063
Sponsors and Collaborators
German High-Grade Non-Hodgkin's Lymphoma Study Group
Investigators
Study Chair: Michael G.M. Pfreundschuh, MD Universitaetsklinikum des Saarlandes
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00052936     History of Changes
Other Study ID Numbers: CDR0000269015, DSHNHL-1999-1A, EU-20243
Study First Received: January 24, 2003
Last Updated: March 11, 2010
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
stage III grade 1 follicular lymphoma
stage III grade 3 follicular lymphoma
stage III grade 2 follicular lymphoma
stage I adult T-cell leukemia/lymphoma
stage II adult T-cell leukemia/lymphoma
stage III adult T-cell leukemia/lymphoma
stage IV adult T-cell leukemia/lymphoma
contiguous stage II adult lymphoblastic lymphoma
noncontiguous stage II adult lymphoblastic lymphoma
stage I adult lymphoblastic lymphoma
stage III adult lymphoblastic lymphoma
stage IV adult lymphoblastic lymphoma
contiguous stage II adult diffuse large cell lymphoma
noncontiguous stage II adult diffuse large cell lymphoma
stage I adult diffuse large cell lymphoma
stage III adult diffuse large cell lymphoma
stage IV adult diffuse large cell lymphoma
contiguous stage II mantle cell lymphoma
noncontiguous stage II mantle cell lymphoma
stage I mantle cell lymphoma
stage III mantle cell lymphoma
stage IV mantle cell lymphoma
contiguous stage II adult Burkitt lymphoma
noncontiguous stage II adult Burkitt lymphoma
stage I adult Burkitt lymphoma
stage III adult Burkitt lymphoma
stage IV adult Burkitt lymphoma
contiguous stage II marginal zone lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Prednisone
Rituximab
Vincristine
Alkylating Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators

ClinicalTrials.gov processed this record on October 23, 2014